NCT07930884 Continuous Glucose Monitoring Parameter and Oral Glucose Tolerance Testing (OGTT) Parameters in Children and Young Adults With Cystic Fibrosis (CF)
| NCT ID | NCT07930884 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Northwell Health |
| Condition | Cystic Fibrosis Related Diabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-06-23 |
| Primary Completion | 2027-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-06-23 with a primary completion date of 2027-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
As modulator therapies extend the lifespan of CF patients, the detection of complications like Cystic Fibrosis Related Diabetes (CFRD) becomes increasingly vital. The current gold standard for CFRD screening, the 2-hour OGTT, is cumbersome and suffers from low compliance. This study proposes that Continuous Glucose Monitoring (CGM) could offer a more comprehensive, easier, and potentially more compliant screening method. The research aims to correlate various CGM parameters (e.g., time in hyperglycemia) with traditional glycemic markers like OGTT glucose levels, GMI, average glucose, variability, and HbA1c. Additionally, the research seeks to understand patient and parent/guardian preferences for CFRD screening modalities. This prospective observational study will involve CF patients wearing a Dexcom CGM around the time of standard OGTT and HbA1c tests, followed by surveys, with the ultimate goal of paving the way for CGM to improve early detection and management of dysglycemia in CF children.
Eligibility Criteria
Inclusion Criteria: 1. Patients with Cystic Fibrosis 2. 10-25 years of age who have obtained or will obtain a OGTT within 3 months of recruitment and CGM placement. Exclusion Criteria: 1. Diagnosis of diabetes mellitus type 1 or type 2 2. Use of the following medication: steroid course, Metformin therapy, 3. Concurrent CV disease or malignancy, kidney failure, lung transplant. 4. Does not have access to personal Bluetooth device compatible with Dexcom G7 application.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07930884 clinical trial?
This trial is open to participants of all sexes, aged 10 Years or older, up to 25 Years, studying Cystic Fibrosis Related Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07930884 currently recruiting?
Yes, NCT07930884 is actively recruiting participants. Contact the research team at japsan@northwell.edu for enrollment information.
Where is the NCT07930884 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT07930884 clinical trial?
NCT07930884 is sponsored by Northwell Health. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.